Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today

By Cory Renauer – Apr 3, 2018 at 11:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Just-released trial results suggest a grim future for fostamatinib as a treatment for one rare disease.

What happened

Shares of Rigel Pharmaceuticals (RIGL -2.87%), a clinical-stage biotech, were down around 21% as of 11:44 a.m. EDT on Tuesday. Investors are reacting to a mid-stage clinical trial failure involving the company's lead treatment candidate, fostamatinib.

So what 

The FDA is reviewing Rigel's application to make fostamatinib a first-in-class treatment for perhaps 65,000 underserved patients with a rare blood disorder called immune thrombocytopenic purpura (ITP). Fostamatinib performed well among ITP patients. However, it failed to show a significant benefit in a study as a treatment for immunoglobulin A (IgA) nephropathy, for which the patient population is roughly twice as large as ITP's.

Anxious looking person looking at their computer screen.

Image source: Getty Images.

Investigators randomized 76 IgA nephropathy patients into groups receiving a placebo, or fostamatinib different dosages. The trial was designed to measure how much protein leaked from their kidneys -- a measurement of disease activity -- and enrolled patients leaking 500 mg per day. There were differences in the rates of improvement between groups, but they weren't strong enough to be considered statistically significant.

Now what

Rigel was able to point to an interesting subgroup analysis that suggests its candidate could still have a future as a treatment for IgA nephropathy. Among the 45 patients with damaged kidneys leaking a full gram of protein per day, the differences were much wider. The median kidney damage reduction from baseline was 36% for patients given 150 mg of fostamatinib versus just 14% in the placebo group.

Although these results warrant further study, Rigel doesn't appear willing to direct its limited resources in this direction right now. Instead, management stated it would seek a partner to help fund such development down the road.

The FDA is expected to deliver a decision about fostamatinib's ITP application by April 17, so don't be surprised if the stock bounces back, or plummets in the days ahead based on the regulator's ruling.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
RIGL
$1.19 (-2.87%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.